Clinical Trial Update: Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ziprasidone for improving insulin sensitivity in people with schizophrenia at risk for diabetes; study completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Metabolic Syndrome
• Schizophrenia

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: Veterans Medical Research Foundation | Conditions: Schizophrenia, Metabolic Syndrome X | Phase 4 | Status: COMPLETED | Results posted: 2020-08-21